Reporting positive and eagerly anticipated, potentially wider label-enabling data from a pair of phase IIb trials, Heron Therapeutics Inc.'s non-opioid HTX-011 took another leap forward on the road to marketing approval in postoperative pain, leaving farther behind any concerns regarding the recent add-on indication for Exparel (bupivacaine liposome injectable suspension) from Pacira Pharmaceuticals Inc.